戊型肝炎的免疫预防
Immunization against Hepatitis E.
机构信息
Center for Vaccine Innovation and Access, PATH, Washington, D.C. 20001.
International Vaccine Institute, SNU Research Park, Gwanak-gu, Seoul 08826, Korea.
出版信息
Cold Spring Harb Perspect Med. 2018 Nov 1;8(11):a032573. doi: 10.1101/cshperspect.a032573.
Abstract
Soon after the 1991 molecular cloning of hepatitis E virus (HEV), recombinant viral capsid antigens were expressed and tested in nonhuman primates for protection against liver disease and infection. Two genotype 1 subunit vaccine candidates entered clinical development: a 56 kDA vaccine expressed in insect cells and HEV 239 vaccine expressed in Both were highly protective against hepatitis E and acceptably safe. The HEV 239 vaccine was approved in China in 2011, but it is not yet prequalified by the World Health Organization, a necessary step for introduction into those low- and middle-income countries where the disease burden is highest. Nevertheless, the stage is set for the final act in the hepatitis E vaccine story-policymaking, advocacy, and pilot introduction of vaccine in at-risk populations, in which it is expected to be cost-effective.
摘要
1991 年丙型肝炎病毒（HEV）的分子克隆后不久，重组病毒衣壳抗原在非人类灵长类动物中进行了表达和测试，以预防肝病和感染。两种基因型 1 亚单位疫苗候选物进入临床开发：一种在昆虫细胞中表达的 56kDa 疫苗和一种在酵母中表达的 HEV 239 疫苗。这两种疫苗都能高度预防戊型肝炎，且安全性可以接受。HEV 239 疫苗于 2011 年在中国获得批准，但尚未世界卫生组织预认证，这是将疫苗引入疾病负担最高的低收入和中等收入国家的必要步骤。然而，戊型肝炎疫苗故事的最后一幕——决策制定、宣传和在高危人群中试点引入疫苗——已经准备就绪，预计该疫苗具有成本效益。
相似文献
1
Immunization against Hepatitis E.戊型肝炎的免疫预防
Cold Spring Harb Perspect Med. 2018 Nov 1;8(11):a032573. doi: 10.1101/cshperspect.a032573.
2
Toward the development of a hepatitis E vaccine.朝着开发戊型肝炎疫苗的方向努力。
Virus Res. 2011 Oct;161(1):93-100. doi: 10.1016/j.virusres.2011.05.008. Epub 2011 May 18.
3
Immunogenicity and efficacy of a bacterially expressed HEV ORF3 peptide, assessed by experimental infection of primates.经灵长类动物实验感染评估，一种由细菌表达的戊型肝炎病毒 ORF3 肽的免疫原性和功效。
Arch Virol. 2009;154(10):1641-8. doi: 10.1007/s00705-009-0496-4. Epub 2009 Sep 15.
4
Evaluation of autophagy induction on HEV 239 vaccine immune response in a mouse model.评估自噬诱导对小鼠模型中 HEV 239 疫苗免疫应答的影响。
IUBMB Life. 2018 Mar;70(3):207-214. doi: 10.1002/iub.1719. Epub 2018 Jan 25.
5
Different Outcomes of Experimental Hepatitis E Virus Infection in Diverse Mouse Strains, Wistar Rats, and Rabbits.不同小鼠品系、Wistar 大鼠和家兔实验性戊型肝炎病毒感染的不同结局。
Viruses. 2018 Dec 20;11(1):1. doi: 10.3390/v11010001.
6
Evaluation of the protective effects of a nanogel-based vaccine against rabbit hepatitis E virus.评价一种基于纳米凝胶的疫苗对兔戊型肝炎病毒的保护作用。
Vaccine. 2019 Sep 20;37(40):5972-5978. doi: 10.1016/j.vaccine.2019.08.029. Epub 2019 Aug 24.
7
Induction of antibody response against hepatitis E virus (HEV) with recombinant human papillomavirus pseudoviruses expressing truncated HEV capsid proteins in mice.在小鼠中用表达截短型戊型肝炎病毒（HEV）衣壳蛋白的重组人乳头瘤病毒假病毒诱导针对戊型肝炎病毒（HEV）的抗体反应。
Vaccine. 2008 Dec 2;26(51):6602-7. doi: 10.1016/j.vaccine.2008.09.035.
8
Immunogenicity and protective efficacy in rhesus monkeys of a recombinant ORF2 protein from hepatitis E virus genotype 4.戊型肝炎病毒4型重组ORF2蛋白在恒河猴中的免疫原性和保护效果
Arch Virol. 2009;154(3):481-8. doi: 10.1007/s00705-009-0335-7. Epub 2009 Feb 25.
9
Recombinant vaccine against hepatitis E: duration of protective immunity in rhesus macaques.重组戊型肝炎疫苗：恒河猴的保护性免疫持续时间
Vaccine. 2002 Sep 10;20(27-28):3285-91. doi: 10.1016/s0264-410x(02)00314-6.
10
Design and immunogenicity analysis of the combined vaccine against zoonotic hepatitis E and foot-and-mouth disease.设计和联合疫苗针对人畜共患戊型肝炎和口蹄疫的免疫原性分析。
Vaccine. 2019 Oct 31;37(46):6922-6930. doi: 10.1016/j.vaccine.2019.09.036. Epub 2019 Oct 8.
引用本文的文献
1
Vaccination Strategies and Research Gaps in Hepatitis E Virus for Special Populations.戊型肝炎病毒针对特殊人群的疫苗接种策略及研究空白
Vaccines (Basel). 2025 Jun 9;13(6):621. doi: 10.3390/vaccines13060621.
2
Immunogenicity, Efficacy, and Effectiveness of Two-Dose and Shorter Schedules of Hepatitis E Vaccine: A Systematic Review.戊型肝炎疫苗两剂次及更短接种程序的免疫原性、效力和效果：一项系统评价
Vaccines (Basel). 2024 Dec 31;13(1):28. doi: 10.3390/vaccines13010028.
3
Progress and Challenges to Hepatitis E Vaccine Development and Deployment.戊型肝炎疫苗研发与推广的进展及挑战
Vaccines (Basel). 2024 Jun 28;12(7):719. doi: 10.3390/vaccines12070719.
4
Evaluation and Immunogenicity of Combined Liposome-Based Vaccine Candidates against Hepatitis E and B Viruses in Rhesus Monkeys.恒河猴中基于脂质体的戊型肝炎和乙型肝炎联合候选疫苗的评估及免疫原性
Vaccines (Basel). 2024 Jan 5;12(1):53. doi: 10.3390/vaccines12010053.
5
Seroprevalence of hepatitis E virus (HEV) among male craft and manual workers in Qatar (2020-2021).卡塔尔男性手工业和体力劳动者中戊型肝炎病毒（HEV）的血清流行率（2020 - 2021年）
Heliyon. 2023 Oct 31;9(11):e21404. doi: 10.1016/j.heliyon.2023.e21404. eCollection 2023 Nov.
6
The Full Value of Vaccine Assessments (FVVA): a framework for assessing and communicating the value of vaccines for investment and introduction decision-making.疫苗评估的全部价值（FVVA）：评估和沟通疫苗投资和引入决策价值的框架。
BMC Med. 2023 Jul 4;21(1):229. doi: 10.1186/s12916-023-02929-0.
7
Recent Advances in Protective Vaccines against Hepatitis Viruses: A Narrative Review.近年来肝炎病毒保护性疫苗的研究进展：叙述性综述。
Viruses. 2023 Jan 12;15(1):214. doi: 10.3390/v15010214.
8
A Historical Review of Military Medical Strategies for Fighting Infectious Diseases: From Battlefields to Global Health.抗击传染病的军事医学策略历史回顾：从战场到全球健康
Biomedicines. 2022 Aug 22;10(8):2050. doi: 10.3390/biomedicines10082050.
9
Hepatitis E Virus in People Who Use Crack-Cocaine: A Cross-Sectional Study in a Remote Region of Northern Brazil.在使用 Crack-cocaine 的人群中戊型肝炎病毒：巴西北部偏远地区的一项横断面研究。
Viruses. 2021 May 17;13(5):926. doi: 10.3390/v13050926.
10
Closer and closer? Maternal immunization: current promise, future horizons.越来越近？母体免疫接种：当前的承诺，未来的前景。
J Perinatol. 2020 Jun;40(6):844-857. doi: 10.1038/s41372-020-0668-3. Epub 2020 Apr 27.
本文引用的文献
1
Classification and Genomic Diversity of Enterically Transmitted Hepatitis Viruses.肠道传播肝炎病毒的分类和基因组多样性。
Cold Spring Harb Perspect Med. 2018 Sep 4;8(9):a031880. doi: 10.1101/cshperspect.a031880.
2
Dynamics of 8G12 competitive antibody in "prime-boost" vaccination of Hepatitis E vaccine.8G12竞争抗体在戊型肝炎疫苗“初免-加强”接种中的动力学
Hum Vaccin Immunother. 2017 Jun 3;13(6):1-6. doi: 10.1080/21645515.2017.1291105. Epub 2017 Mar 8.
3
Modeling the long-term antibody response of a hepatitis E vaccine.模拟戊型肝炎疫苗的长期抗体反应。
Vaccine. 2015 Aug 7;33(33):4124-9. doi: 10.1016/j.vaccine.2015.06.050. Epub 2015 Jun 28.
4
A Comprehensive Study of Neutralizing Antigenic Sites on the Hepatitis E Virus (HEV) Capsid by Constructing, Clustering, and Characterizing a Tool Box.通过构建、聚类和表征一个工具库对戊型肝炎病毒（HEV）衣壳上的中和抗原位点进行全面研究。
J Biol Chem. 2015 Aug 7;290(32):19910-22. doi: 10.1074/jbc.M115.649764. Epub 2015 Jun 17.
5
Hepatitis E vaccine: WHO position paper, May 2015.戊型肝炎疫苗：世界卫生组织立场文件，2015年5月
Wkly Epidemiol Rec. 2015 May 1;90(18):185-200.
6
Long-term efficacy of a hepatitis E vaccine.戊型肝炎疫苗的长期疗效。
N Engl J Med. 2015 Mar 5;372(10):914-22. doi: 10.1056/NEJMoa1406011.
7
Bacteria expressed hepatitis E virus capsid proteins maintain virion-like epitopes.细菌表达的戊型肝炎病毒衣壳蛋白保留病毒样表位。
Vaccine. 2014 May 19;32(24):2859-65. doi: 10.1016/j.vaccine.2014.02.025. Epub 2014 Mar 22.
8
Protection against hepatitis E virus infection by naturally acquired and vaccine-induced immunity.自然获得性免疫和疫苗诱导免疫对戊型肝炎病毒感染的保护作用。
Clin Microbiol Infect. 2014 Jun;20(6):O397-405. doi: 10.1111/1469-0691.12419. Epub 2013 Nov 18.
9
Immunogenicity and safety of hepatitis E vaccine in healthy hepatitis B surface antigen positive adults.戊型肝炎疫苗在健康乙型肝炎表面抗原阳性成年人中的免疫原性和安全性。
Hum Vaccin Immunother. 2013 Nov;9(11):2474-9. doi: 10.4161/hv.25814. Epub 2013 Jul 25.
10
Hepatitis E vaccine development: a 14 year odyssey.戊型肝炎疫苗的研发历程：十四年的探索。
Hum Vaccin Immunother. 2012 Jun;8(6):823-7. doi: 10.4161/hv.20042. Epub 2012 Jun 1.
Zotero 插件